The Development of Therapeutic Radiographers in Imaging and Adaptive Radiotherapy Through Clinical Trial Quality Assurance.


Journal

Clinical oncology (Royal College of Radiologists (Great Britain))
ISSN: 1433-2981
Titre abrégé: Clin Oncol (R Coll Radiol)
Pays: England
ID NLM: 9002902

Informations de publication

Date de publication:
07 2021
Historique:
received: 26 10 2020
revised: 29 01 2021
accepted: 17 02 2021
pubmed: 27 3 2021
medline: 26 11 2021
entrez: 26 3 2021
Statut: ppublish

Résumé

Adaptive radiotherapy (ART) is an emerging advanced treatment option for bladder cancer patients. Therapeutic radiographers (RTTs) are central to the successful delivery of this treatment. The purpose of this work was to evaluate the image-guided radiotherapy (IGRT) and ART experience of RTTs before participating in the RAIDER trial. A plan of the day (PoD) quality assurance programme was then implemented. Finally, the post-trial experience of RTTs was evaluated, together with the impact of trial quality assurance participation on their routine practice. A pre-trial questionnaire to assess the experience of the RTT staff group in IGRT and ART in bladder cancer was sent to each centre. Responses were grouped according to experience. The PoD quality assurance programme was implemented, and the RAIDER trial commenced. During stage 1 of the trial, RTTs reported difficulties in delivering PoD and the quality assurance programme was updated accordingly. A follow-up questionnaire was sent assessing experience in IGRT and ART post-trial. Any changes in routine practice were also recorded. The experience of RTTs in IGRT and ART pre-trial varied. For centres deemed to have RTTs with more experience, the initial PoD quality assurance programme was streamlined. For RTTs without ART experience, the full quality assurance programme was implemented, of which 508 RTTs completed. The quality assurance programme was updated (as the trial recruited) and it was mandated that at least one representative RTT (regardless of pre-trial experience) participated in the update in real-time. The purpose of the updated quality assurance programme was to provide further support to RTTs in delivering a complex treatment. Engagement with the updated quality assurance programme was high, with RTTs in 24/33 centres participating in the real-time online workshop. All 33 UK centres reported all RTTs reviewed the updated training offline. Post-trial, the RTTs' experience in IGRT and ART was increased. Overall, 508 RTTs undertook the PoD quality assurance programme. There was a high engagement of RTTs in the PoD quality assurance programme and trial. RTTs increased their experience in IGRT and ART and subsequently updated their practice for bladder cancer and other treatment sites.

Identifiants

pubmed: 33766503
pii: S0936-6555(21)00052-2
doi: 10.1016/j.clon.2021.02.009
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

461-467

Subventions

Organisme : Department of Health
ID : ICA-SCL-2018-04-ST2-002
Pays : United Kingdom
Organisme : Cancer Research UK
ID : CRUK/14/016
Pays : United Kingdom
Organisme : Cancer Research UK
ID : CRUK/12/055
Pays : United Kingdom

Informations de copyright

Copyright © 2021 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Auteurs

A Webster (A)

National Radiotherapy Trials Quality Assurance Group, Mount Vernon Cancer Centre, London, UK. Electronic address: Amanda.webster2@nhs.net.

S Hafeez (S)

Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.

R Lewis (R)

Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK.

C Griffins (C)

Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK.

K Warren-Oseni (K)

The Royal Marsden NHS Foundation Trust, London, UK.

E Patel (E)

University College Hospital, London, UK.

V N Hansen (VN)

Odense University Hospital, Odense, Denmark.

E Hall (E)

Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK.

R Huddart (R)

Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.

E Miles (E)

National Radiotherapy Trials Quality Assurance Group, Mount Vernon Cancer Centre, London, UK.

H A McNair (HA)

Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH